Alpha-Galactosidase, Serum
Alpha-galactosidase is the enzyme responsible for the degradation of ceramide trihexoside (globotriaosylceramide). Fabry disease is an X-linked recessive disorder that results in deficiency of alpha-galactosidase and the intra-lysosomal accumulation of ceramide trihexoside in many cell types. The alpha-galactosidase gene (GLA) is located on the long arm of the X-chromosome between Xq21.33 and Xq22 and at least 630 different mutations have been identified in the individuals diagnosed with Fabry disease. The accumulation of ceramide trihexoside (globotriaosylceramide) in vascular endothelium results in renal impairment, neuropathic pain, cardiac dysfunction and cutaneous angiokeratomas. The onset of symptoms typically occurs in late childhood or early adolescence with the characteristic manifestation of burning pain and paraesthesias in the extremities (Fabry crisis). In later stages, the disease is characterized by purple skin lesions, corneal dystrophy and chronic kidney disease followed by cardiovascular and cerebrovascular disease.
Diagnosis of the Fabry disease is made by demonstrating decreased or absence activity of alpha-galactosidase in serum, leukocytes or cultured fibroblasts. Neonatal blood spots can be used for the screening in a high-risk population. The measurement of alpha-galactosidase has limited value to identify female carriers as most have normal levels of alpha-galactosidase.
- Diagnosis of Fabry disease in males
- Screening for Fabry disease in high risk population
- Deficiency of alpha-galactosidase is diagnostic for Fabry disease in males
- Males with classic Fabry disease have <1% α-Gal A enzyme activity.
- Males with atypical Fabry disease have residual enzyme activity >1% of normal.
- Female carriers usually have alpha-galactosidase levels in the normal range
- Genetic testing by sequence analysis of the GLA gene is recommended as the appropriate diagnostic test identifying carriers
Serum
- 0.074 – 0.457 U/L
Leukocytes
- > 23.1 nmol/hour/mg protein
Serum (SST)
Stability
- Ambient: not recommended
- Refrigerated: 24 hours
- Frozen: 14 days (Preferred)
- J Lab Clin Med. 1973;81:157-71. [PMID: 4683418]
- J Genet Couns. 2013;22:555-64. [PMID: 23860966]
- Genet Med. 2015;17:323-30. [PMID: 25232851]
- Mol Genet Metab. 2016;117:104-13. [PMID: 26546059]
- Hart P, Galtrey CM, et al. Biochemical aspect of neurological disease. Clinical Biochemistry metabolic and clinical aspects. 3rd ed. 2014. Page 683-701.